Powered by

OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients; --Analysis triggered after meeting enrollment milestone of 200 patients--; --Topline data anticipated second half of 2021--

Jan 26, 2021 - Business Wire

OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, announced today that its ORP-101 molecule successfully cleared its first interim futility analysis in a Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).

"We are pleased to have passed this important milestone for our lead compound, ORP-101, and for the company," said Gary Phillips, M.D., President and Chief Executive Officer of OrphoMed. "We contin...